Literature DB >> 7647329

Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.

I Soubeyran1, J Wafflart, F Bonichon, I de Mascarel, M Trojani, M Durand, A Avril, J M Coindre.   

Abstract

To assess the practical prognostic value of pS2, we evaluated its expression by immunohistochemistry in paraffin-embedded tissue from 942 previously untreated invasive ductal carcinomas (IDC) resected in our center between 1980 and 1986. Positive staining of tumor cells was found in 684 cases (73%), but most of the tumors contained only a small amount of positive cells. There was a negative correlation between pS2 and tumor size (p = 0.01) and histological grade (p < 0.0001), and a positive correlation between pS2 and hormonal receptor status (p < 0.001). With respect to overall survival, pS2 positivity was associated with a better prognosis for the whole group and the node-positive sub-group. However, in terms of relapse and metastasis, pS2 was not significant. Furthermore, in multivariate analysis including tumor size, nodal status, histological grade, ER status, PR status, chemotherapy, hormonal treatment, and pS2, the latter appears to be of no prognostic value.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647329     DOI: 10.1007/bf00665784

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  [Prognostic value of a continuous variable and an optimal cutoff point].

Authors:  C Hill
Journal:  Bull Cancer       Date:  1993-08       Impact factor: 1.276

2.  Problems in dichotomizing continuous variables.

Authors:  D G Altman
Journal:  Am J Epidemiol       Date:  1994-02-15       Impact factor: 4.897

3.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7.

Authors:  S B Jakowlew; R Breathnach; J M Jeltsch; P Masiakowski; P Chambon
Journal:  Nucleic Acids Res       Date:  1984-03-26       Impact factor: 16.971

4.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

5.  Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

Authors:  M C Rio; J P Bellocq; B Gairard; U B Rasmussen; A Krust; C Koehl; H Calderoli; V Schiff; R Renaud; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.

Authors:  M C Rio; J P Bellocq; J Y Daniel; C Tomasetto; R Lathe; M P Chenard; A Batzenschlager; P Chambon
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

7.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.

Authors:  J A Foekens; W L van Putten; H Portengen; H Y de Koning; B Thirion; J Alexieva-Figusch; J G Klijn
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

8.  pS2 protein and steroid hormone receptors in invasive breast carcinomas.

Authors:  F C Koerner; D E Goldberg; S M Edgerton; L H Schwartz
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

9.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Authors:  L H Schwartz; F C Koerner; S M Edgerton; J M Sawicka; M C Rio; J P Bellocq; P Chambon; A D Thor
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

10.  Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.

Authors:  V Cappelletti; D Coradini; E Scanziani; E Benini; R Silvestrini; G Di Fronzo
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

View more
  8 in total

1.  Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.

Authors:  S J Reshkin; T Tedone; M Correale; A Mangia; V Casavola; A Paradiso
Journal:  Cell Prolif       Date:  1999 Apr-Jun       Impact factor: 6.831

2.  The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases.

Authors:  N Quénel; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

3.  Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.

Authors:  G MacGrogan; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 4.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

5.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

Authors:  G MacGrogan; L Mauriac; M Durand; F Bonichon; M Trojani; I de Mascarel; J M Coindre
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

6.  Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.

Authors:  Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738

7.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

8.  pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

Authors:  I Soubeyran; N Quénel; J M Coindre; F Bonichon; M Durand; J Wafflart; L Mauriac
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.